Report overview
Diabetes drugs are treatments for diabetes by lowering the sugar lower in the blood. Diabetes is a kind of disease with common symptoms such as frequent urination, increased thirst and weight loss. The most common drugs used are insulin and oral medications.
This report contains market size and forecasts of Hypoglycemic Drugs in global, including the following market information:
Global Hypoglycemic Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Hypoglycemic Drugs Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Hypoglycemic Drugs companies in 2021 (%)
The global Hypoglycemic Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Insulin Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hypoglycemic Drugs include Sanofi, Merck & Co., Novo Nordisk, Eli Lilly, Boehringer Ingelheim, Novartis, Johnson & Johnson, AstraZeneca and Takeda, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hypoglycemic Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hypoglycemic Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Hypoglycemic Drugs Market Segment Percentages, by Type, 2021 (%)
Insulin
DPP-4
GLP-1
SGLT-2
Other
Global Hypoglycemic Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Hypoglycemic Drugs Market Segment Percentages, by Application, 2021 (%)
Type 1 Diabetes
Type 2 Diabetes
Global Hypoglycemic Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Hypoglycemic Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hypoglycemic Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Hypoglycemic Drugs revenues share in global market, 2021 (%)
Key companies Hypoglycemic Drugs sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Hypoglycemic Drugs sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Sanofi
Merck & Co.
Novo Nordisk
Eli Lilly
Boehringer Ingelheim
Novartis
Johnson & Johnson
AstraZeneca
Takeda
Bayer
Tonghua DongBao
Hua Dong
